Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial
Related Posts
Unger ER, Lin JS, Wisk LE, Yu H, L'Hommedieu M, Lavretsky H, Montoy JCC, Gottlieb MA, Rising KL, Gentile NL, Santangelo M, Venkatesh AK, Rodriguez[...]
Landovitz RJ, Delany-Moretlwe S, Fogel JM, Eshleman SH, Marzinke MA, Piwowar-Manning E, Richardson P, Halvas EK, Mellors JW, Persaud D, Kofron R, McCauley M, Rose[...]
El-Zein RS, Mohammed M, Nguyen DD, Hill CL Jr, Thomas L, Nassif M, DeVore AD, Albert NM, Butler J, Patterson JH, Williams FB, Hernandez A,[...]